Klotho upregulation by rapamycin protects against vascular disease in CKD.
Level V
Where this comes from
- Record sourced from PubMed, PMID 26422620.
- Also identified by DOI 10.1038/ki.2015.223.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Medial arterial calcification involves chondrogenic/osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Zhao et al. report that phosphate activates the mammalian target of rapamycin (mTOR) cascade in VSMCs, leading to downregulation of Klotho. Furthermore, rapamycin was shown to halt medial calcification. This effect was blunted in the absence of Klotho. Given the concomitant anti-atherosclerotic effects of the mTOR inhibitor, this agent has clinical potential as an inhibitor of intimal atherosclerosis and medial calcification.
Medical subject headings
- Aorta, Abdominal
- Aorta, Thoracic
- Aortic Diseases
- Glucuronidase
- Protein Kinase Inhibitors
- Sirolimus
- TOR Serine-Threonine Kinases
- Vascular Calcification